Options for Prevention of Cytomegalovirus Disease

Editorials1 April 1991Options for Prevention of Cytomegalovirus DiseaseHenry H. Balfour Jr., MDHenry H. Balfour Jr., MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-7-598 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCytomegalovirus is the major cause of infection after solid organ or bone marrow transplantation (1, 2). Cytomegalovirus is also a problem for other groups of patients, especially neonates and persons with the acquired immunodeficiency syndrome (AIDS). Therefore, control of this pernicious virus is a high priority. In 1983, I wrote an Annals editorial titled, "Cytomegalovirus Disease: Can It Be Prevented?" (3). The juxtaposition of that title with the present one, "Options for Prevention of Cytomegalovirus Disease," emphasizes that progress indeed has been made.This issue contains the final report by Plotkin and colleagues (4) demonstrating the safety and efficacy of...References1. MeyersFlournoyThomas JNE. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-88. CrossrefMedlineGoogle Scholar2. PetersonFergusonFrydBalfourRynasiewiczSimmons PRDHJR. Infectious diseases in hospitalized renal transplant recipients: a prospective study of a complex and evolving problem. Medicine (Baltimore). 1982;61:360-72. CrossrefMedlineGoogle Scholar3. Balfour H. Cytomegalovirus disease: can it be prevented? [Editorial]. Ann Intern Med. 1983;98:544-6. LinkGoogle Scholar4. PlotkinStarrFriedman SSH Effect of Towne live vaccine on cytomegalovirus disease in patients receiving renal transplants: a controlled trial. Ann Intern Med. 1990;114:525-31. LinkGoogle Scholar5. Betts R. Cytomegalovirus vaccine in renal transplants. [Editorial]. Ann Intern Med. 1979;91:780-2. LinkGoogle Scholar6. SnydmanWernerHeinze-Lacey DBB. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renaltransplant recipients. N Engl J Med. 1987;317:1049-54. CrossrefMedlineGoogle Scholar7. BalfourChaceStapletonSimmonsFryd HBJRD. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989;320:1381-7. CrossrefMedlineGoogle Scholar8. Davis C. The prevention of cytomegalovirus disease in renal transplantation. Am J Kidney Dis. 1990;16:175-88. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Henry H. BalfourJr., MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUpdated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ TransplantationInternational Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ TransplantationFailure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplantsAcyclovir in preventing cytomegalovirus infection in kidney transplant recipients: A case-controlled studyBone Marrow Transplantation: A ReviewHerpesVirus Infections: State of the ArtAcyclovir To Prevent Cytomegalovirus Infection after Renal TransplantationTony Wong, MD, Olivier Toupance, MD, Jacques Chanard, MD 1 April 1991Volume 114, Issue 7Page: 598-599KeywordsAIDSBone marrow transplantationCytomegalovirus infectionInfantsInfectious diseasesSafety ePublished: 1 December 2008 Issue Published: 1 April 1991 PDF downloadLoading ...